Intervacc AB Total Assets
Intervacc AB total assets. Based on the latest financial reports, Intervacc AB (IVACC) holds total assets worth Skr329.23 Million SEK (≈ $35.43 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Intervacc AB for the company's overall valuation and market capitalisation.
Total Assets of Intervacc AB (2013–2024)
Total assets of Intervacc AB from 2013 to 2024. This chart illustrates how Intervacc AB's total assets have evolved over time, based on quarterly financial data. See IVACC stock price for real-time trading data and today's change.
Intervacc AB - Asset Composition Analysis
Intervacc AB Total Assets Breakdown (December 2024)
Intervacc AB total assets breakdown as of December 2024. Intervacc AB's total assets of Skr329.23 Million consist of 26.9% current assets and 73.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 18.4% |
| Accounts Receivable | Skr2.37 Million | 1.3% |
| Inventory | Skr11.42 Million | 6.1% |
| Property, Plant & Equipment | Skr665.00K | 0.4% |
| Intangible Assets | Skr136.26 Million | 72.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Intervacc AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Intervacc AB (IVACC) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intervacc AB's current assets represent 26.9% of total assets in 2024, an increase from 10.4% in 2013.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2024, up from 6.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 6.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 72.8% of total assets.
Intervacc AB Competitors by Total Assets
Key competitors of Intervacc AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Intervacc AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.00 | 2.60 | 9.65 |
| Quick Ratio | 9.53 | 2.26 | 9.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr186.89 Million | Skr39.22 Million | Skr151.40 Million |
Intervacc AB - Advanced Valuation Insights
This section examines the relationship between Intervacc AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -27.8% |
| Total Assets | Skr187.32 Million |
| Market Capitalization | $31.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intervacc AB's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Intervacc AB's assets decreased by 27.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intervacc AB (2013–2024)
The table below shows the annual total assets of Intervacc AB from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr187.32 Million ≈ $20.16 Million |
-27.85% |
| 2023-12-31 | Skr259.61 Million ≈ $27.94 Million |
-2.05% |
| 2022-12-31 | Skr265.04 Million ≈ $28.52 Million |
-19.54% |
| 2021-12-31 | Skr329.39 Million ≈ $35.45 Million |
-7.29% |
| 2020-12-31 | Skr355.28 Million ≈ $38.23 Million |
+49.87% |
| 2019-12-31 | Skr237.07 Million ≈ $25.51 Million |
+16.98% |
| 2018-12-31 | Skr202.66 Million ≈ $21.81 Million |
+12.81% |
| 2017-12-31 | Skr179.64 Million ≈ $19.33 Million |
+9.77% |
| 2016-12-31 | Skr163.66 Million ≈ $17.61 Million |
+5.62% |
| 2015-12-31 | Skr154.96 Million ≈ $16.68 Million |
+0.03% |
| 2014-12-31 | Skr154.92 Million ≈ $16.67 Million |
+194.33% |
| 2013-12-31 | Skr52.63 Million ≈ $5.66 Million |
-- |
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more